I was diagnosed with Extensive DCIS, estrogen receptor positive with a very small amount of microinvasion cancerous cells. I had a bilateral mastectomy and my medical oncologist has given me an option to take or not take tamoxifen. I am just trying to get some feedback so I can make the right decision. I just had a unilateral mastectomy due to recent diagnosis for breast cancer (DCIS grade 3 with less than 1mm micro-invasion, 5 lymph nodes removed and tested negative, 0/5, BRAC 1 and 2 gene tested negative). The oncologist said I do not need chemo or radiation, but want me to take Tamoxifen for at least 5 years. Now I am very struggling on whether to take it or not. I really need other patients' help on deciding if I should take Tamoxifen or not. The only reason that I don't want to take the Tamoxifen is because I am scared about getting the possibility of having endometrial cancer, sometimes, my endometrial thickness is already a concern by the radiologist, thus I am desperately hoping to seek real-life experiences and advice from anyone here who has already gone through this. My questions are: If you have taken Tamoxifen for years, have you suffered from any significant side effects (particularly uterine or endometrial cancer)? Like you double masectomy on Tamoxifen three years because Estrogen Positive and pre menopausal. This is a new view as I think too many people get it back after five years in my opinion (as did my mum) and they appear to be trying to prolong it to that length of time. If you had opted not to take Tamoxifen years ago, do you still think it's a good decision or a decision you regret about now? BUT my oncologist is very proactive on keeping fit and eventually I could virtually not move and had to stop going to my beloved fun gym classes. What is the recommended dosage of levaquin Propranolol package insert Purchase obagi tretinoin cream Apr 27, 2012. A handful of atypical cells one week; a double mastectomy and reconstructive. Five days after surgery, I was pronounced completely cured. However, if the DCIS is throughout the breast, a mastectomy will probably be necessary. There is no reason to remove lymph nodes for small areas of DCIS since. The decision to take tamoxifen for DCIS is a difficult one for many women, as the. you consider a bilateral prophylactic mastectomy removal of both breasts. Do Not Do Recommendation. Do not offer tamoxifen or raloxifene to women who were at high risk of breast cancer but have had a bilateral mastectomy. I have so much to say in this post I don’t even know where to start. And that promise to work on being less wordy – well, not today! I say if you don’t speak up, your doctor will just naturally assume (and rightfully so) that everything’s fine. As I mentioned in my previous post, the three FDA approved drugs most commonly prescribed for adjuvant hormonal therapy for post-menopausal early stage , HR-positive breast cancer patients are anastrozole (Arimidex®), letrozole (Femera®) and exemestane (Aromasin®). I’m a firm believer that a good rant now and then is a good thing, even a healthy thing, so that’s one reason I’m sharing about my experience with the dark side of aromatase inhibitors. If a whole bunch of us don’t speak up about whatever the issue might be, why should we expect things to ever change? It should also be noted that such drugs are also sometimes used for other purposes, such as treatment of metastatic breast cancer and even for prevention purposes. First of all, many women hesitate to talk about the nasty side effects of AIs because they don’t want to be perceived as complainers or whiners. AIs have been proven to be effective in preventing recurrence. This is a good thing and it’s important to take them and keep taking them if one has been prescribed for you and you are able to tolerate it. I am not suggesting and would never suggest that a woman do otherwise. The side effects of all three of these drugs are similar and include bone loss, weight gain, fatigue, hair loss, vaginal dryness, loss of libido, joint pain, insomnia and bone fractures to name a few. And of course, some of these same side effects also affect some women taking Tamoxifen. In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant improvements in progression-free survival compared with fulvestrant plus placebo in patients with metastatic breast cancer. Identification of patients most suitable for the addition of palbociclib to endocrine therapy after tumour recurrence is crucial for treatment optimisation in metastatic breast cancer. We aimed to confirm our earlier findings with this extended follow-up and show our results for subgroup and biomarker analyses. In this multicentre, double-blind, randomised phase 3 study, women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy were stratified by sensitivity to previous hormonal therapy, menopausal status, and presence of visceral metastasis at 144 centres in 17 countries. Eligible patients—ie, any menopausal status, Eastern Cooperative Oncology Group performance status 0–1, measurable disease or bone disease only, and disease relapse or progression after previous endocrine therapy for advanced disease during treatment or within 12 months of completion of adjuvant therapy—were randomly assigned (2:1) via a centralised interactive web-based and voice-based randomisation system to receive oral palbociclib (125 mg daily for 3 weeks followed by a week off over 28-day cycles) plus 500 mg fulvestrant (intramuscular injection on days 1 and 15 of cycle 1; then on day 1 of subsequent 28-day cycles) or placebo plus fulvestrant. The primary endpoint was investigator-assessed progression-free survival. We also assessed endocrine therapy resistance by clinical parameters, quantitative hormone-receptor expression, and tumour Between Oct 7, 2013, and Aug 26, 2014, 521 patients were randomly assigned, 347 to fulvestrant plus palbociclib and 174 to fulvestrant plus placebo. Study enrolment is closed and overall survival follow-up is in progress. Tamoxifen after double mastectomy Analyzing the risk of recurrence after mastectomy for DCIS a new., Ductal Carcinoma in Situ DCIS Dr Susan Love Foundation Sildenafil in dogsDoxycycline how it works Mastectomy may be recommended for women with multifocal disease, and. No mortality benefit for tamoxifen after DCIS has been conclusively. IBIS-II An international, double-blind, randomised placebo-controlled trial. Tamoxifen Initiation After Ductal Carcinoma In Situ - NCBI - NIH. Do not offer tamoxifen or raloxifene to women who were at high risk.. Why a Double Mastectomy? It's Complicated Catherine Guthrie. Methods. In this multicentre, double-blind, randomised phase 3 study, women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast. Arimidex official prescribing information for healthcare professionals. Includes indications, dosage, adverse reactions, pharmacology and more. Risk factors for breast cancer are female sex and advancing age, inherited risk, breast density, obesity, alcohol consumption, and exposure to ionizing.